A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.
Berenson, James R
A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research Mar 2007 - 1762-8 p. digital
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1078-0432
10.1158/1078-0432.CCR-06-1812 doi
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Arsenic Trioxide
Arsenicals--administration & dosage
Ascorbic Acid--administration & dosage
Boronic Acids--administration & dosage
Bortezomib
Disease-Free Survival
Female
Humans
Male
Middle Aged
Multiple Myeloma--drug therapy
Oxides--administration & dosage
Pyrazines--administration & dosage
Recurrence
Survival Analysis
Treatment Failure
Treatment Outcome
A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research Mar 2007 - 1762-8 p. digital
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1078-0432
10.1158/1078-0432.CCR-06-1812 doi
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Arsenic Trioxide
Arsenicals--administration & dosage
Ascorbic Acid--administration & dosage
Boronic Acids--administration & dosage
Bortezomib
Disease-Free Survival
Female
Humans
Male
Middle Aged
Multiple Myeloma--drug therapy
Oxides--administration & dosage
Pyrazines--administration & dosage
Recurrence
Survival Analysis
Treatment Failure
Treatment Outcome